INmune Bio signs strategic commercialization agreement with Uniphar for named-patient access to Ebstrocel in Europe, MENA

INmune Bio announced a strategic commercialization agreement with Uniphar establishing a global commercialization framework for Ebstrocel, initially providing named-patient access in selected European and MENA markets as a capital-efficient foundation for broader commercialization.

Detected & updated continuously · Source: Nebula